1. |
Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26(21): 3543-3551.
|
2. |
Schallier D, Decoster L, De Greve J. Pemetrexed-induced hyperpigmentation of the skin. Anticancer Res, 2011, 31(5): 1753-1755.
|
3. |
Piérard-Franchimont C, Quatresooz P, Reginster MA, et al. Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett, 2011, 2(5): 769-772.
|
4. |
Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol, 2002, 13(5): 737-741.
|
5. |
Buchinger K, Stahel R, Niggemeier V, et al. Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma. Lung Cancer, 2013, 80(3): 347-349.
|
6. |
袁晓荣, 孟令茹, 于焕欣, 等. 培美曲塞治疗后致皮肤色素沉着 1 例. 临床荟萃, 2015, 30(4): 443-444.
|
7. |
赵元鹏, 李凤兰. 培美曲塞化疗后皮肤色素沉着 1 例. 临床肿瘤学杂志, 2013, 18(6): 575-576.
|
8. |
National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. (2009-05-28)[2017-11-03]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
|